​

LENZ Therapeutics Stock (NASDAQ:LENZ)

ForecastRevenueOwnershipFinancialsChartTranscripts
LENZ Therapeutics by TradingView

Previous Close

$5.33

52W Range

$4.54 - $50.40

50D Avg

$5.26

200D Avg

$11.29

Market Cap

$153.95M

Avg Vol (3M)

$874.45K

Beta

1.63

Div Yield

-

LENZ Company Profile

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

152

IPO Date

Jun 25, 2021

Website

LENZ Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25
License$17.50M
Product$1.59M

Fiscal year ends in Dec 25 | Currency in USD

LENZ Financial Summary

Dec 25Dec 24Dec 23
Revenue$19.09M--
Operating Income$-91.14M$-58.61M$-72.43M
Net Income$-82.13M$-49.77M$-69.97M
EBITDA$-91.14M$-49.71M$-72.41M
Basic EPS$-2.85$-2.34$-15.30
Diluted EPS$-2.85$-2.34$-15.30

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Aug 11, 26 | 4:30 PM
Q1 26May 11, 26 | 4:30 PM
Q4 25Mar 24, 26 | 8:30 AM

Peer Comparison

TickerCompany
TYRATyra Biosciences, Inc.
NBTXNanobiotix S.A.
GHRSGH Research PLC
MRVIMaravai LifeSciences Holdings, Inc.
ABUSArbutus Biopharma Corp
GERNGeron Corporation
RZLTRezolute, Inc.
SVRASavara Inc.
SPRYARS Pharmaceuticals, Inc.
PRMEPrime Medicine, Inc.